Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | Zendy

Maha Hussain | Zendy; Joaquı́n Mateo | Zendy; Karim Fizazi | Zendy; Fred Saad | Zendy; Neal D. Shore | Zendy; Shahneen Sandhu | Zendy; Kim N. | Zendy; Oliver Sartor | Zendy; Neeraj Agarwal | Zendy; David Olmos | Zendy; Antoine Thiery-Vuillemin | Zendy; Przemyslaw Twardowski | Zendy; Guilhem Roubaud | Zendy; Mustafa Özgüroğlu | Zendy; Jinyu Kang | Zendy; Joseph E. Burgents | Zendy; Christopher Gresty | Zendy; Claire Corcoran | Zendy; Carrie A. Adelman | Zendy; Johann S. de Bono | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Author(s) -

Maha Hussain,

Joaquı́n Mateo,

Karim Fizazi,

Fred Saad,

Neal D. Shore,

Shahneen Sandhu,

Kim N.,

Oliver Sartor,

Neeraj Agarwal,

David Olmos,

Antoine Thiery-Vuillemin,

Przemyslaw Twardowski,

Guilhem Roubaud,

Mustafa Özgüroğlu,

Jinyu Kang,

Joseph E. Burgents,

Christopher Gresty,

Claire Corcoran,

Carrie A. Adelman,

Johann S. de Bono

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2022485

Subject(s) - olaparib , prostate cancer , oncology , medicine , cancer research , cancer , biology , poly adp ribose polymerase , biochemistry , polymerase , gene

We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The results of the final analysis of overall survival have not yet been reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research